BlueAllele

Executive Summary

BlueAllele is a San Diego-based biotechnology company developing a novel gene correction platform called PALIDON, which leverages the non-homologous end joining (NHEJ) DNA repair pathway to enable precise and durable edits in non-dividing cells. Founded in 2018, the company aims to address the limitations of traditional gene editing methods, which are inefficient in post-mitotic tissues such as the brain, eye, and muscle. By designing repair templates optimized for NHEJ, BlueAllele's approach offers potential advantages in safety, durability, and applicability across a broad range of genetic diseases. The company is currently in the preclinical stage, with its platform validated in early studies. Although financial details and specific pipeline assets are undisclosed, BlueAllele's technology represents a compelling advancement in the gene therapy landscape. The company's focus on hard-to-treat tissues and its differentiated mechanism position it well for future growth, but execution risks remain given the early stage and competitive CRISPR field.

Upcoming Catalysts (preview)

• H2 2026Series A or B Financing Round70% success
• H1 2027Preclinical Proof-of-Concept Data in Leading Indication60% success
• 2027Strategic Partnership with Major Pharma40% success